Researchers suggest that MultiCell could potentially be used to discern early patterns of disease, such as in asthma.
Despite the partial share placement, Mutares remains a long-term anchor shareholder in Terranor, holding a 57 percent stake. The firm will continue to actively support Terranor’s strategic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback